Ongoing launch of CASGEVY® continues to gain momentum--2025 is poised to be a catalyst-rich year with key updates across several ...

Shares of CRISPR Therapeutics CRSP have lost more than 30% in the past year. Though the stock soared at the onset of 2024, ...

Some investors believe you make money when you buy a stock, not when you sell it. The logic behind this idea is that ...

Analyst Gil Blum from Needham maintained a Buy rating on Crispr Therapeutics AG (CRSP – Research Report) and keeping the price target at ...

Recent TAU study demonstrates how a crucial but underexplored process of DNA transfer between bacteria affects its defense ...

CRISPR-Cas9 is one of the biggest discoveries of the 21st century. Since it was developed in 2012, this gene-editing tool has revolutionized biology research, making it easier to study disease and ...

Researchers at the Broad Institute of MIT and Harvard have developed a gene-editing treatment for prion disease that extends ...

including a study of CRISPR Therapeutics and Vertex Pharma’s CRISPR ex vivo drug for blood disorders beta thalassaemia and sickle cell disease. Allergan and Editas say they will test AGN-151587 ...

CRISPR-based therapies are also being developed ... TDT in 2022 and launched at a one-off cost of $2.8 million. A recent study estimated the lifetime cost of TDT to be $5.4 million, spit between ...

In this article, we are going to take a look at where CRISPR Therapeutics AG (NASDAQ:CRSP) stands against other biotech stocks with the biggest upside potential. Improving Trends for Biotech ...